Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AIMTNASDAQ:ARQTNASDAQ:ESPRNASDAQ:ODTNASDAQ:PHAT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AARQTArcutis Biotherapeutics$8.88+1.6%$10.11$1.76▼$15.21$859.67M1.144.64 million shs960,244 shsESPREsperion Therapeutics$2.10+0.2%$2.44$0.70▼$3.40$396.80M0.846.73 million shs4.54 million shsODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsPHATPhathom Pharmaceuticals$9.23+1.9%$9.76$6.07▼$17.02$540.14M0.63832,853 shs243,986 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%ARQTArcutis Biotherapeutics-2.24%-13.47%-9.05%+91.67%-34.19%ESPREsperion Therapeutics+9.42%+9.42%-8.73%+2.96%+71.31%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%PHATPhathom Pharmaceuticals+0.55%-9.67%-17.79%+35.22%-12.97%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AARQTArcutis Biotherapeutics1.0231 of 5 stars3.41.00.00.00.02.50.6ESPREsperion Therapeutics3.6979 of 5 stars3.22.00.03.93.40.80.6ODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APHATPhathom Pharmaceuticals1.7835 of 5 stars3.40.00.00.01.74.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune TherapeuticsN/AN/AN/AN/AARQTArcutis Biotherapeutics2.75Moderate Buy$26.56199.05% UpsideESPREsperion Therapeutics2.40Hold$9.33345.51% UpsideODTOdonate TherapeuticsN/AN/AN/AN/APHATPhathom Pharmaceuticals2.75Moderate Buy$21.33131.13% UpsideCurrent Analyst RatingsLatest AIMT, ESPR, ARQT, ODT, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/19/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.004/12/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.004/11/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.004/10/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/1/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.003/25/2024ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/25/2024ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/22/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.003/15/2024PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.002/28/2024ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $11.002/28/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $16.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AARQTArcutis Biotherapeutics$59.61M14.42N/AN/A$0.94 per share9.45ESPREsperion Therapeutics$116.33M3.41N/AN/A($3.85) per share-0.54ODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/APHATPhathom Pharmaceuticals$680K794.32N/AN/A($1.27) per share-7.27Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AARQTArcutis Biotherapeutics-$262.14M-$3.92N/AN/AN/A-439.79%-294.85%-78.57%5/14/2024 (Estimated)ESPREsperion Therapeutics-$209.25M-$2.12N/A6.76N/A-179.87%N/A-91.62%5/7/2024 (Confirmed)ODTOdonate Therapeutics-$126.35MN/A0.00N/AN/AN/AN/AN/AN/APHATPhathom Pharmaceuticals-$201.59M-$3.88N/AN/AN/AN/AN/A-63.40%5/8/2024 (Estimated)Latest AIMT, ESPR, ARQT, ODT, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AESPREsperion Therapeutics-$0.17N/A+$0.17N/AN/AN/A 3/7/2024Q4 2023PHATPhathom Pharmaceuticals-$0.92-$0.80+$0.12-$0.21$0.93 million$0.68 million 2/27/202412/31/2023ARQTArcutis Biotherapeutics-$0.64-$0.72-$0.08-$0.72$11.78 million$13.53 million 2/27/202412/31/2023ESPREsperion Therapeutics-$0.53-$0.50+$0.03-$0.50$26.84 million$32.25 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40ARQTArcutis Biotherapeutics2.287.086.80ESPREsperion TherapeuticsN/A1.290.87ODTOdonate TherapeuticsN/AN/AN/APHATPhathom PharmaceuticalsN/A10.2510.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%ARQTArcutis BiotherapeuticsN/AESPREsperion Therapeutics47.39%ODTOdonate TherapeuticsN/APHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%ARQTArcutis Biotherapeutics20.70%ESPREsperion Therapeutics1.00%ODTOdonate Therapeutics48.90%PHATPhathom Pharmaceuticals24.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableARQTArcutis Biotherapeutics29696.81 million76.77 millionOptionableESPREsperion Therapeutics240189.40 million187.51 millionOptionableODTOdonate Therapeutics14528.53 million14.58 millionNot OptionablePHATPhathom Pharmaceuticals45258.52 million44.42 millionOptionableAIMT, ESPR, ARQT, ODT, and PHAT HeadlinesSourceHeadlineNeedham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)markets.businessinsider.com - April 23 at 12:37 PMPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.7%americanbankingnews.com - April 21 at 4:56 AMPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Reaffirmed by Needham & Company LLCamericanbankingnews.com - April 21 at 1:36 AMAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Alimera (ALIM)markets.businessinsider.com - April 19 at 3:21 PMBuy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V oqueznamarkets.businessinsider.com - April 19 at 3:21 PMPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.7% marketbeat.com - April 19 at 1:59 PM12 Most Shorted Stocks in 2024finance.yahoo.com - April 19 at 1:05 PMVanguard Group Inc. Has $19.94 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)marketbeat.com - April 15 at 4:14 AMPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 3%americanbankingnews.com - April 14 at 3:14 AMPhathom Pharmaceuticals CFO sells over $38k in company stockinvesting.com - April 12 at 8:50 PMPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.2% After Insider Sellingmarketbeat.com - April 11 at 12:24 PMPhathom Pharmaceuticals (NASDAQ:PHAT) Rating Reiterated by Needham & Company LLCmarketbeat.com - April 11 at 8:32 AMMolly Henderson Sells 3,435 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stockinsidertrades.com - April 11 at 6:48 AMBuy Rating Justified by Rhythm Pharmaceuticals’ Strong Market Entry and Promising Pipelinemarkets.businessinsider.com - April 10 at 1:19 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)markets.businessinsider.com - April 9 at 10:35 AMPhathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analystmsn.com - April 7 at 8:26 AMOptimistic Outlook for Phathom Pharmaceuticals’ Voquezna Despite Prescription Data Fluctuationsmarkets.businessinsider.com - April 6 at 9:29 AMARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investorsfinance.yahoo.com - April 5 at 7:28 PMPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 5.5%marketbeat.com - April 4 at 3:08 PMPhathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - April 3 at 8:05 AMPhathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 3 at 8:00 AMPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 8.1%marketbeat.com - April 2 at 3:17 PMAnalysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Phathom Pharmaceuticals (PHAT)markets.businessinsider.com - April 1 at 5:09 PMPhathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid"stockhouse.com - March 28 at 10:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAimmune TherapeuticsNASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Arcutis BiotherapeuticsNASDAQ:ARQTArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Esperion TherapeuticsNASDAQ:ESPREsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Odonate TherapeuticsNASDAQ:ODTOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Phathom PharmaceuticalsNASDAQ:PHATPhathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.